|
A phase II clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors. |
|
|
Consulting or Advisory Role - Celgene |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Tesaro |
Travel, Accommodations, Expenses - Bayer; Celgene; Tesaro |
|
|
Consulting or Advisory Role - Oncoscience; Roche/Genentech; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Celgene |
Travel, Accommodations, Expenses - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
Travel, Accommodations, Expenses - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Novartis; Roche/Genentech |
Research Funding - AstraZeneca |
Expert Testimony - AstraZeneca |
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Novartis; Roche/Genentech |
Other Relationship - Abbvie; Bristol-Myers Squibb; Celgene; Epizyme; Novartis |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Celgene (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Research Funding - Celgene |